Pharmafile Logo
Pharmafocus logo
Advanced Search

Allergan ready to take a loss by selling Teva shares

November 2, 2017
Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …

News

Novartis reveals the data behind its showdown with Gilead

November 1, 2017
Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

News
csm_tk12_17_rupert_sandbrink_kl_fb0c325239

Topas Therapeutics brings in new CMO

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Topas Therapeutics, biotech, drugs, pharma, pharmaceutical

Topas Therapeutics, a German company focused on developing novel therapeutics to treat immune-mediated and autoimmune diseases, announced that it has …

Appointment
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature
roche

Roche’s Tecentriq approved for funding in UK in bladder cancer

November 1, 2017
Research and Development, Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical

In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the …

News

Indivior’s opioid addiction treatment recommended by FDA advisory panel

November 1, 2017
Research and Development, Sales and Marketing FDA, RGP-6000, Trump, US, indivior, opioid crisis, opioids

Another step has been made in the fight back against the ongoing opioid crisis in the US as it emerges …

News

CEO and President implicated as price-fixing probe widens

November 1, 2017
Research and Development, Sales and Marketing Mylan, Teva, biotech, drugs, pharma, pharmaceutical

A group of states, 45 members-strong, has expanded its probe into the generics pharmaceutical industry by expanding its case to …

News
astrazeneca-sign

AstraZeneca asthma therapy tralokinumab flops at Phase 3

November 1, 2017
Research and Development AstraZeneca, MedImmune, asthma, pharma

AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …

News
nhs_sign

Cancer death rates 61% higher in poorer areas

November 1, 2017
Medical Communications, Research and Development NHS, biotech, drugs, pharma, pharmaceutical

Figures released by NHS Scotland have revealed that the numbers of deaths from cancer are 67% higher in the poorest …

News
shire_image_4

Shire to streamline operations with 100-strong plant sale and in-house Cinryze production

October 31, 2017
Manufacturing and Production, Sales and Marketing Cinryze, Shire, pharma

Shire has revealed that it plans to sell one of its manufacturing sites in Milford, Massachusetts, having already entered active …

News
alzheimers_brain

Over-the-counter multinutrient drink could have beneficial impact on Alzheimer’s, new study reveals

October 31, 2017
Manufacturing and Production, Research and Development Alzheimer's, Fortasyn Connect, Souvenaid, dementia

LipiDiDiet, a European project investigating “the impact of nutritional lipids on neuronal and cognitive performance in ageing, Alzheimer’s disease and …

News

Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma

October 31, 2017
Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis

Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …

News
amgen_hq

Kirin Holdings to withdraw from 30 year venture with Amgen, sell shares for $780m

October 31, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Kirin, joint venture, pharma

Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal

October 30, 2017
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

News

MSD withdraws European application of Keytruda combo in lung cancer

October 30, 2017
Sales and Marketing EMA, MSD, keytruda

MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …

News
astrazeneca_sign_sky

AstraZeneca licenses genetic disease drug to Mereo Biopharma for $5 million, becomes shareholder

October 30, 2017
Sales and Marketing AstraZeneca, Mereo BioPharma, pharma

AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin deficiency, to Mereo Biopharma for …

News
novartis_window

Novartis to bolster oncology portfolio with $3.9 billion acquisition

October 30, 2017
Sales and Marketing Advanced Acclerator Applications, Lutathera, Novartis, pharma

Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce …

News
merckentranceweb

Samsung Biologics reinforces biologic manufacturing and development partnership with MSD

October 30, 2017
Manufacturing and Production, Sales and Marketing Korea, MSD, Samsung BioLogics, pharma

Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the …

News
pfizer-building-logo1web

Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

October 30, 2017
Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …

News
online_survey_icon_or_logo

Collaboration in Biopharma

October 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical

Dear Colleague,

Feature
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026